

# Miguel E Quiñones-Mateu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1998101/publications.pdf>

Version: 2024-02-01

105  
papers

4,029  
citations

109321

35  
h-index

133252

59  
g-index

108  
all docs

108  
docs citations

108  
times ranked

4339  
citing authors

#	ARTICLE	IF	CITATIONS
1	Human epithelial $\beta$ -defensins 2 and 3 inhibit HIV-1 replication. <i>Aids</i> , 2003, 17, F39-F48.	2.2	388
2	Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. <i>Journal of Virology</i> , 1995, 69, 23-31.	3.4	240
3	A Dual Infection/Competition Assay Shows a Correlation between Ex Vivo Human Immunodeficiency Virus Type 1 Fitness and Disease Progression. <i>Journal of Virology</i> , 2000, 74, 9222-9233.	3.4	224
4	Comparing the Ex Vivo Fitness of CCR5-Tropic Human Immunodeficiency Virus Type 1 Isolates of Subtypes B and C. <i>Journal of Virology</i> , 2003, 77, 1021-1038.	3.4	189
5	The Replicative Fitness of Primary Human Immunodeficiency Virus Type 1 (HIV-1) Group M, HIV-1 Group O, and HIV-2 Isolates. <i>Journal of Virology</i> , 2005, 79, 8979-8990.	3.4	179
6	Deep sequencing: Becoming a critical tool in clinical virology. <i>Journal of Clinical Virology</i> , 2014, 61, 9-19.	3.1	123
7	Prion seeding activity and infectivity in skin samples from patients with sporadic Creutzfeldt-Jakob disease. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	103
8	Role of Human $\beta$ -defensins in HIV Infection. <i>Advances in Dental Research</i> , 2006, 19, 42-48.	3.6	84
9	Fitness of drug resistant HIV-1: methodology and clinical implications. <i>Drug Resistance Updates</i> , 2002, 5, 224-233.	14.4	82
10	Variable Sensitivity of CCR5-Tropic Human Immunodeficiency Virus Type 1 Isolates to Inhibition by RANTES Analogs. <i>Journal of Virology</i> , 2000, 74, 4868-4876.	3.4	81
11	Impact of tuberculosis on HIV-1 replication, diversity, and disease progression. <i>AIDS Reviews</i> , 2002, 4, 165-76.	1.0	81
12	Use of Four Next-Generation Sequencing Platforms to Determine HIV-1 Coreceptor Tropism. <i>PLoS ONE</i> , 2012, 7, e49602.	2.5	78
13	Role of the Human Immunodeficiency Virus Type 1 Envelope Gene in Viral Fitness. <i>Journal of Virology</i> , 2003, 77, 9069-9073.	3.4	77
14	Diminished Replicative Fitness of Primary Human Immunodeficiency Virus Type 1 Isolates Harboring the K65R Mutation. <i>Journal of Clinical Microbiology</i> , 2005, 43, 1395-1400.	3.9	76
15	Increased Levels of Human Beta-Defensins mRNA in Sexually HIV-1 Exposed But Uninfected Individuals. <i>Current HIV Research</i> , 2008, 6, 531-538.	0.5	74
16	HIV tropism: diagnostic tools and implications for disease progression and treatment with entry inhibitors. <i>Aids</i> , 2006, 20, 1359-1367.	2.2	71
17	Human Immunodeficiency Virus Type 1 (HIV-1) Quasispecies at the Sites of Mycobacterium tuberculosis Infection Contribute to Systemic HIV-1 Heterogeneity. <i>Journal of Virology</i> , 2002, 76, 1697-1706.	3.4	66
18	Analysis of pol Gene Heterogeneity, Viral Quasispecies, and Drug Resistance in Individuals Infected with Group O Strains of Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 1998, 72, 9002-9015.	3.4	64

#	ARTICLE	IF	CITATIONS
19	Sensitive Deep-Sequencing-Based HIV-1 Genotyping Assay To Simultaneously Determine Susceptibility to Protease, Reverse Transcriptase, Integrase, and Maturation Inhibitors, as Well as HIV-1 Coreceptor Tropism. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2167-2185.	3.2	61
20	Characterization of the Reverse Transcriptase of a Human Immunodeficiency Virus Type 1 Group O Isolate. <i>Virology</i> , 1997, 236, 364-373.	2.4	60
21	In Vitro Intersubtype Recombinants of Human Immunodeficiency Virus Type 1: Comparison to Recent and Circulating In Vivo Recombinant Forms. <i>Journal of Virology</i> , 2002, 76, 9600-9613.	3.4	51
22	Reduced Fitness of HIV-1 Resistant to Cxcr4 Antagonists. <i>Antiviral Therapy</i> , 2003, 8, 1-8.	1.0	51
23	Low-Frequency Drug Resistance in HIV-Infected Ugandans on Antiretroviral Treatment Is Associated with Regimen Failure. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3380-3397.	3.2	49
24	Use of a novel assay based on intact recombinant viruses expressing green (EGFP) or red (DsRed2) fluorescent proteins to examine the contribution of pol and env genes to overall HIV-1 replicative fitness. <i>Journal of Virological Methods</i> , 2006, 136, 102-117.	2.1	47
25	Mucosal Transmission of Human Immunodeficiency Virus. <i>Current HIV Research</i> , 2012, 10, 3-8.	0.5	46
26	Performance comparison of next generation sequencing analysis pipelines for HIV-1 drug resistance testing. <i>Scientific Reports</i> , 2020, 10, 1634.	3.3	45
27	Combination of a mutagenic agent with a reverse transcriptase inhibitor results in systematic inhibition of HIV-1 infection. <i>Virology</i> , 2005, 338, 1-8.	2.4	41
28	Drug Resistance, Virus Fitness and HIV-1 Mutagenesis. <i>Current Pharmaceutical Design</i> , 2004, 10, 4065-4070.	1.9	41
29	Mechanisms Involved in Stimulation of Human Immunodeficiency Virus Type 1 Replication by Aminoxyypentane RANTES. <i>Journal of Virology</i> , 2001, 75, 8624-8638.	3.4	40
30	Insertions in the Reverse Transcriptase Increase both Drug Resistance and Viral Fitness in a Human Immunodeficiency Virus Type 1 Isolate Harboring the Multi-Nucleoside Reverse Transcriptase Inhibitor Resistance 69 Insertion Complex Mutation. <i>Journal of Virology</i> , 2002, 76, 10546-10552.	3.4	40
31	Current tests to evaluate HIV-1 coreceptor tropism. <i>Current Opinion in HIV and AIDS</i> , 2009, 4, 136-142.	3.8	40
32	Activation of antigen-induced lymphocyte proliferation by interleukin-15 without the mitogenic effect of interleukin-2 that may induce human immunodeficiency virus-1 expression.. <i>Journal of Clinical Investigation</i> , 1996, 98, 616-621.	8.2	38
33	A novel TaqMan real-time PCR assay to estimate ex vivo human immunodeficiency virus type 1 fitness in the era of multi-target (pol and env) antiretroviral therapy. <i>Journal of General Virology</i> , 2003, 84, 2217-2228.	2.9	37
34	Fitness Variations and their Impact on the Evolution of Antiretroviral Drug Resistance. <i>Current Drug Targets Infectious Disorders</i> , 2003, 3, 355-371.	2.1	37
35	Chronic opioid use modulates human enteric microbiota and intestinal barrier integrity. <i>Gut Microbes</i> , 2021, 13, 1946368.	9.8	36
36	Point Mutant Frequencies in the <i>pol</i> Gene of Human Immunodeficiency Virus Type 1 Are Two- to Threefold Lower Than Those of <i>env</i> . <i>AIDS Research and Human Retroviruses</i> , 1996, 12, 1117-1128.	1.1	35

#	ARTICLE	IF	CITATIONS
37	Cystic Fibrosis and Normal Human Airway Epithelial Cell Response to Influenza A Viral Infection.. Journal of Interferon and Cytokine Research, 2006, 26, 609-627.	1.2	35
38	Greater Diversity of HIV-1 Quasispecies in HIV-Infected Individuals With Active Tuberculosis. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 24, 408-417.	2.1	34
39	Functional Characterization of Chimeric Reverse Transcriptases with Polypeptide Subunits of Highly Divergent HIV-1 Group M and O Strains. Journal of Biological Chemistry, 2001, 276, 27470-27479.	3.4	32
40	Failure to Detect Human Immunodeficiency Virus Type 1 Superinfection in 28 HIV-Seroconcordant Individuals with High Risk of Reexposure to the Virus. AIDS Research and Human Retroviruses, 2004, 20, 1026-1031.	1.1	32
41	Viral Drug Resistance and Fitness. Advances in Pharmacology, 2008, 56, 257-296.	2.0	30
42	HIV type 1 tropism and inhibitors of viral entry: clinical implications. AIDS Reviews, 2006, 8, 60-77.	1.0	30
43	Human Immunodeficiency Virus Type 1 Resistance or Cross-Resistance to Nonnucleoside Reverse Transcriptase Inhibitors Currently under Development as Microbicides. Antimicrobial Agents and Chemotherapy, 2011, 55, 1403-1413.	3.2	29
44	Next-Generation Sequencing to Help Monitor Patients Infected with HIV: Ready for Clinical Use?. Current Infectious Disease Reports, 2014, 16, 401.	3.0	28
45	LTR and tat variability of HIV-1 isolates from patients with divergent rates of disease progression. Virus Research, 1998, 57, 11-20.	2.2	27
46	Role of Baseline pol Genotype in HIV-1 Fitness Evolution. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 33, 448-460.	2.1	25
47	Molecular Characterization of Human Immunodeficiency Virus Type 1 Isolates from Venezuela. AIDS Research and Human Retroviruses, 1995, 11, 605-616.	1.1	23
48	Novel Method for Simultaneous Quantification of Phenotypic Resistance to Maturation, Protease, Reverse Transcriptase, and Integrase HIV Inhibitors Based on 3'Gag(p2/p7/p1/p6)/PR/RT/INT-Recombinant Viruses: a Useful Tool in the Multitarget Era of Antiretroviral Therapy. Antimicrobial Agents and Chemotherapy, 2011, 55, 3729-3742.	3.2	23
49	Absence of HIV-1 Drug Resistance Mutations Supports the Use of Dolutegravir in Uganda. AIDS Research and Human Retroviruses, 2018, 34, 404-414.	1.1	23
50	Tapering Courses of Oral Vancomycin Induce Persistent Disruption of the Microbiota That Provide Colonization Resistance to Clostridium difficile and Vancomycin-Resistant Enterococci in Mice. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	23
51	HIV type 1 integrase inhibitors: from basic research to clinical implications. AIDS Reviews, 2008, 10, 172-89.	1.0	23
52	Sequence Note:envGene Characterization of the First HIV Type 1 Group O Spanish Isolate. AIDS Research and Human Retroviruses, 1996, 12, 1647-1649.	1.1	21
53	3'-Azido-2-Deoxythymidine (AZT) Mediates Cross-Resistance to Nucleoside Analogs in the Case of AZT-Resistant Human Immunodeficiency Virus Type 1 Variants. Journal of Virology, 1998, 72, 4858-4865.	3.4	21
54	Persistent Replication of Human Immunodeficiency Virus Type 1 despite Treatment of Pulmonary Tuberculosis in Dually Infected Subjects. Vaccine Journal, 2005, 12, 1298-1304.	3.1	20

#	ARTICLE	IF	CITATIONS
55	Sensitive Cell-Based Assay for Determination of Human Immunodeficiency Virus Type 1 Coreceptor Tropism. <i>Journal of Clinical Microbiology</i> , 2013, 51, 1517-1527.	3.9	18
56	Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay. <i>AIDS Research and Therapy</i> , 2018, 15, 18.	1.7	17
57	Greater Diversity of HIV-1 Quasispecies in HIV-Infected Individuals With Active Tuberculosis. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2000, 24, 408-417.	2.1	16
58	Can HIV-1 superinfection compromise antiretroviral therapy?. <i>Aids</i> , 2004, 18, 131-134.	2.2	16
59	Editorial: [Hot Topic: Use of Microbicides to Prevent HIV Sexual Transmission (Guest Editor: Miguel E.)] <i>ETQq1 1 0,784314 rgBT / Overl</i>	0.5	16
60	Novel high throughput pooled shRNA screening identifies NQO1 as a potential drug target for host directed therapy for tuberculosis. <i>Scientific Reports</i> , 2016, 6, 27566.	3.3	16
61	HIV/AIDS in Sierra Leone: Characterizing the Hidden Epidemic. <i>AIDS Reviews</i> , 2019, 20, 104-113.	1.0	16
62	Identification of Variants in Primary and Recurrent Glioblastoma Using a Cancer-Specific Gene Panel and Whole Exome Sequencing. <i>PLoS ONE</i> , 2015, 10, e0124178.	2.5	16
63	Methods to Determine HIV-1 Ex Vivo Fitness. , 2005, 304, 355-368.		15
64	Sorting out the complexities of HIV-1 fitness. <i>Aids</i> , 2003, 17, 780-781.	2.2	15
65	Novel Recombinant Virus Assay for Measuring Susceptibility of Human Immunodeficiency Virus Type 1 Group M Subtypes To Clinically Approved Drugs. <i>Journal of Clinical Microbiology</i> , 2009, 47, 2232-2242.	3.9	13
66	High-level resistance to bictegravir and cabotegravir in subtype A- and D-infected HIV-1 patients failing raltegravir with multiple resistance mutations. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2965-2974.	3.0	13
67	Contribution of Human Immunodeficiency Virus Type 1 Minority Variants to Reduced Drug Susceptibility in Patients on an Integrase Strand Transfer Inhibitor-Based Therapy. <i>PLoS ONE</i> , 2014, 9, e104512.	2.5	12
68	Increased replication capacity following evolution of PYxE insertion in Gagâ€³6 is associated with enhanced virulence in HIVâ€³1 subtype C from East Africa. <i>Journal of Medical Virology</i> , 2017, 89, 106-111.	5.0	12
69	Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3525-3533.	3.0	12
70	Mechanisms of clinical resistance by HIV-I variants to zidovudine and the paradox of reverse transcriptase sensitivity. <i>Drug Resistance Updates</i> , 1998, 1, 21-28.	14.4	11
71	Molecular Epidemiology of HIV Type 1 Isolates from the Czech Republic: Identification of an env E Subtype Case. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 85-89.	1.1	11
72	Phylogeny of HIV Type 1 Group O Isolates Based on env Gene Sequences. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 769-773.	1.1	11

#	ARTICLE	IF	CITATIONS
73	Is HIV-1 evolving to a less virulent (pathogenic) virus?. <i>Aids</i> , 2005, 19, 1689-1690.	2.2	11
74	Sensitive detection of HIV-1 resistance to Zidovudine and impact on treatment outcomes in low- to middle-income countries. <i>Infectious Diseases of Poverty</i> , 2017, 6, 163.	3.7	11
75	Emergence of Resistance to Colistin During the Treatment of Bloodstream Infection Caused by <i>Klebsiella pneumoniae</i> Carbapenemase-Producing <i>Klebsiella pneumoniae</i> . <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy054.	0.9	11
76	<i>In Vivo</i> Emergence of a Novel Protease Inhibitor Resistance Signature in HIV-1 Matrix. <i>MBio</i> , 2020, 11, .	4.1	11
77	Resistance Mutations outside the Integrase Coding Region Have an Effect on Human Immunodeficiency Virus Replicative Fitness but Do Not Affect Its Susceptibility to Integrase Strand Transfer Inhibitors. <i>PLoS ONE</i> , 2013, 8, e65631.	2.5	10
78	Perspective: the nose and the stomach play a critical role in the N2ACE2-Pari* (modified ACE2) drug treatment project of SARS-CoV-2 infection. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 553-560.	3.0	10
79	Reduced fitness of HIV-1 resistant to CXCR4 antagonists. <i>Antiviral Therapy</i> , 2003, 8, 1-8.	1.0	10
80	Identification of low-molecular weight inhibitors of HIV-1 reverse transcriptase using a cell-based high-throughput screening system. <i>Antiviral Research</i> , 2011, 91, 94-98.	4.1	9
81	Impaired human immunodeficiency virus type 1 replicative fitness in atypical viremic non-progressor individuals. <i>AIDS Research and Therapy</i> , 2017, 14, 15.	1.7	9
82	Sequence Note: env Gene Diversity of HIV Type 1 Isolates from Spain. <i>AIDS Research and Human Retroviruses</i> , 1996, 12, 955-957.	1.1	8
83	Nucleotide Diversity in Three Different Genomic Regions of Venezuelan HIV Type 1 Isolates: A Subtyping Update. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 73-79.	1.1	8
84	HIV-1 mutagenesis during antiretroviral therapy: implications for successful drug treatment. <i>Frontiers in Bioscience - Landmark</i> , 2005, 10, 743.	3.0	8
85	HIV-1 strains belonging to large phylogenetic clusters show accelerated escape from integrase inhibitors in cell culture compared with viral isolates from singleton/small clusters. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2171-2183.	3.0	8
86	First-line HIV treatment failures in non-B subtypes and recombinants: a cross-sectional analysis of multiple populations in Uganda. <i>AIDS Research and Therapy</i> , 2019, 16, 3.	1.7	8
87	Viral fitness: relation to drug resistance mutations and mechanisms involved: nucleoside reverse transcriptase inhibitor mutations. <i>Current Opinion in HIV and AIDS</i> , 2007, 2, 81-87.	3.8	7
88	Characterization of the First SARS-CoV-2 Isolates from Aotearoa New Zealand as Part of a Rapid Response to the COVID-19 Pandemic. <i>Viruses</i> , 2022, 14, 366.	3.3	7
89	Inhaled modified angiotensin converting enzyme 2 (ACE2) as a decoy to mitigate SARS-CoV-2 infection. <i>New Zealand Medical Journal</i> , 2020, 133, 112-118.	0.5	7
90	Manipulation of Spray-Drying Conditions to Develop an Inhalable Ivermectin Dry Powder. <i>Pharmaceutics</i> , 2022, 14, 1432.	4.5	7

#	ARTICLE	IF	CITATIONS
91	Impact on Replicative Fitness of the G48E Substitution in the Protease of HIV-1. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2008, 48, 255-262.	2.1	6
92	Virus-inhibitory peptide. <i>Aids</i> , 2011, 25, 1663-1664.	2.2	6
93	HIV-1 and GBV-C co-infection in Venezuela. <i>Journal of Infection in Developing Countries</i> , 2014, 8, 863-868.	1.2	6
94	Ultraviolet-C Irradiation, Heat, and Storage as Potential Methods of Inactivating SARS-CoV-2 and Bacterial Pathogens on Filtering Facepiece Respirators. <i>Pathogens</i> , 2022, 11, 83.	2.8	6
95	The impact of viral and host elements on HIV fitness and disease progression. <i>Current HIV/AIDS Reports</i> , 2007, 4, 36-41.	3.1	5
96	Predictors of first-line antiretroviral therapy failure among adults and adolescents living with HIV/AIDS in a large prevention and treatment program in Nigeria. <i>AIDS Research and Therapy</i> , 2020, 17, 64.	1.7	5
97	Reduced and highly diverse peripheral HIV-1 reservoir in virally suppressed patients infected with non-B HIV-1 strains in Uganda. <i>Retrovirology</i> , 2022, 19, 1.	2.0	5
98	Decreased Enteric Bacterial Composition and Diversity in South American Crohn's Disease Vary With the Choice of Treatment Strategy and Time Since Diagnosis. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 791-800.	1.3	4
99	Rapid Response to SARS-CoV-2 in Aotearoa New Zealand: Implementation of a Diagnostic Test and Characterization of the First COVID-19 Cases in the South Island. <i>Viruses</i> , 2021, 13, 2222.	3.3	4
100	Nanoscale flow cytometry reveals interpatient variability in HIV protease activity that correlates with viral infectivity and identifies drug-resistant viruses. <i>Scientific Reports</i> , 2020, 10, 18101.	3.3	3
101	Prior Case of Resistance on Dolutegravir Plus Lamivudine Dual Therapy. <i>AIDS Research and Human Retroviruses</i> , 2020, 36, 254-255.	1.1	2
102	Uncoupling Molecular Testing for SARS-CoV-2 From International Supply Chains. <i>Frontiers in Public Health</i> , 2021, 9, 808751.	2.7	2
103	Chikungunya Virus High Genomic Plasticity Enables Rapid Adaptation to Restrictive A549 Cells. <i>Viruses</i> , 2022, 14, 282.	3.3	2
104	The case for New Zealand to have its own COVID-19 vaccine programme. <i>New Zealand Medical Journal</i> , 2020, 133, 112-115.	0.5	2
105	Human Immunodeficiency Virus Type 1 Resistance or Cross-Resistance to Nonnucleoside Reverse Transcriptase Inhibitors Currently under Development as Microbicides. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3645-3645.	3.2	0